Procaps Group S.A. (PROCF)

Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as blood clot, immunosuppressant, oncology, and analgesics products, as well as personal protective equipment, syringes, double chamber syringes, injection vials and ampoules, sterilized powder products, sterile droppers, and lyophilized solid vials. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, and urological, as well as vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastrointestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides diabetes solutions and chronic disease management tools comprising blood glucose meters, telemonitoring, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract development and manufacturing services for soft gelatin capsule-related and gummy technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands. Sofgen Pharma S.A. was formerly known as Procaps Group S.A. The company was founded in 1977 and is based in Luxembourg, Luxembourg.